Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.50 |
| ▸ | PTPN5 | P54829 | 4/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7813194 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2833832 | 0.79 | FFAR1 (0.44) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL7812261 | 0.78 | CYP3A4 (0.52) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL2841303 | 0.78 | RXRA (0.49) | SLC6A2SLC6A4SLC6A3PTPN5KCNH2 | |
| SCHEMBL7813925 | 0.78 | RXRA (0.49) | SLC6A2SLC6A4SLC6A3PTPN5KCNH2 | |
| SCHEMBL2840125 | 0.78 | DPP4 (0.46) | CYP3A4CYP2D6PTPN5 | |
| SCHEMBL7813919 | 0.78 | DPP4 (0.46) | CYP3A4CYP2D6PTPN5 | |
| SCHEMBL7813356 | 0.76 | CYP3A4 (0.51) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL2836748 | 0.76 | CYP3A4 (0.51) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL2838945 | 0.74 | KDR (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398558-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | claimed |
| WO-2010094659-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | claimed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | claimed |
| US-8367838-B2 | Amines or amino alcohols as GLYT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | KOLCZEWSKI SABINE (DE) | 2012-09-13 | — | — | US | disclosed |
| EP-2398558-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094659-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | SLC6A2 13/4885SLC6A4 33/4885SLC6A3 12/4885 |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | SLC6A2 13/4885SLC6A4 33/4885SLC6A3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.